Home › Funds › Fidelity › Fidelity MSCI Health Care Index ETF
Fund family: Fidelity · Filed by FIDELITY COVINGTON TRUST (CIK 945908) · SEC series S000042575
Ticker: FHLC (C000131667)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 2,773 with, 47 against, 0 abstentions (not counted as with management); 3 items carried no recommendation. Shareholder proposals: 1 FOR, 37 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as Fidelity’s manager page (1,165,189 ballot items across 406 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | Fidelity | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 95.8% | 2,698 | 94.1% | 974,562 |
| Backed environmental and social shareholder proposals at US companies | n/a | 9 | 6.8% | 11,096 |
Each ballot item this fund voted is set against the votes of the other Fidelity funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted differently from most Fidelity funds on 122 items (4.4% of the 2,751 items where a comparison was possible).
| Company | Meeting | Item | This fund | Most Fidelity funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| Moderna, Inc. | 2026-05-06 | To elect two Class II director nominees set forth in the proxy statement, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her other respective successor is duly elected and qualified or such director's earlier death, resignation or removal: Sa | Against | FOR — 73 of 73 Fidelity funds | Against | Elected, 81.0% support |
| Doximity, Inc. | 2025-08-28 | To approve, on a non-binding advisory basis, the compensation paid to the Company's named executive officers for the fiscal year ended March 31, 2025. | Against | FOR — 57 of 57 Fidelity funds | Against | Passed (calculated), 96.4% support |
| Viking Therapeutics, Inc. | 2026-05-19 | TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS. | Against | FOR — 46 of 46 Fidelity funds | Against | Approved, 70.2% support |
| Humana Inc. | 2026-04-16 | Election of Directors: Wayne A. I. Frederick, M.D. | Against | FOR — 41 of 41 Fidelity funds | Against | Elected, 83.4% support |
| Incyte Corporation | 2026-06-08 | Approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers. | Against | FOR — 39 of 39 Fidelity funds | Against | Approved, 83.9% support |
| LifeStance Health Group, Inc. | 2026-06-02 | Election of two director nominees named in the Proxy Statement to serve until the 2029 Annual Meeting of Stockholders: Robert Bessler, M.D. | Withhold | FOR — 39 of 39 Fidelity funds | Against | Elected, 85.1% support |
| Travere Therapeutics, Inc. | 2026-05-19 | To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year. ELECTION OF DIRECTORS: Roy Baynes | Withhold | FOR — 38 of 38 Fidelity funds | Against | Elected, 87.7% support |
| Incyte Corporation | 2026-06-08 | Election of Directors to serve until the 2027 annual meeting of shareholders and thereafter until their successors are duly elected and qualified: Jean-Jacques Bienaime | Against | FOR — 35 of 35 Fidelity funds | Against | Elected, 84.2% support |
| Mirum Pharmaceuticals, Inc. | 2026-06-15 | To elect the Board's three Class III nominees for director to hold office until the Company's 2029 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Timothy Walbert | Withhold | FOR — 33 of 33 Fidelity funds | Against | Elected, 69.7% support |
| Scholar Rock Holding Corporation | 2026-06-04 | To elect four Class II directors to our Board of Directors, each to serve until the 2029 Annual Meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, or removal: Kristina Burow | Withhold | FOR — 36 of 36 Fidelity funds | Against | Elected, 81.6% support |
| Scholar Rock Holding Corporation | 2026-06-04 | To elect four Class II directors to our Board of Directors, each to serve until the 2029 Annual Meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, or removal: Michael Gilman | Withhold | FOR — 36 of 36 Fidelity funds | Against | Elected, 78.2% support |
| Apogee Therapeutics, Inc. | 2026-06-09 | Election of Class III Directors for terms expiring in 2029: William (BJ) Jones, Jr. | Withhold | FOR — 34 of 34 Fidelity funds | Against | Passed (calculated), 81.5% support |
| Penumbra, Inc. | 2026-06-18 | To elect the nominees for Class II director to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Arani Bose, M.D. | Withhold | FOR — 29 of 29 Fidelity funds | Against | Elected, 84.9% support |
| Henry Schein, Inc. | 2026-05-21 | Shareholder Proposal to approve, by non-binding vote, a shareholder proposal to Govern by Majority Vote. | Against | FOR — 29 of 29 Fidelity funds | For | Approved, 57.6% support |
| Universal Health Services, Inc. | 2026-05-20 | Shareholder Stockholder proposal to report votes based on UHS shareholder money at risk, if properly presented at the meeting. | Against | FOR — 26 of 26 Fidelity funds | For | Failed (calculated), 4.7% support |
| Acadia Healthcare Company, Inc. | 2026-05-06 | Election of Directors: Michael J. Fucci | Against | FOR — 24 of 24 Fidelity funds | Against | Elected, 91.0% support |
| MBX Biosciences, Inc. | 2026-06-04 | Election of two Class II Directors, each to serve until the Company's 2029 Annual Meeting of Stockholders or until such person's successor is duly elected and qualified, or until their earlier death, resignation or removal: Edward T. Mathers | Withhold | FOR — 24 of 24 Fidelity funds | Against | Passed (calculated), 80.8% support |
| Alumis Inc. | 2026-06-30 | To elect the three Class II director nominees named below to serve until the Company's 2029 annual meeting of stockholders: Zhengbin (Bing) Yao, Ph.D. | Withhold | FOR — 24 of 24 Fidelity funds | Against | Passed (calculated), 84.1% support |
| Labcorp Holdings Inc. | 2026-05-21 | Election of the members of the Company's Board of Directors: Garheng Kong, M.D., Ph.D. | Against | FOR — 21 of 21 Fidelity funds | Against | Elected, 71.4% support |
| Denali Therapeutics Inc. | 2026-06-03 | ELECTION OF DIRECTORS: Jennifer Cook | Withhold | FOR — 21 of 21 Fidelity funds | Against | Elected, 60.9% support |
| Harmony Biosciences Holdings, Inc. | 2026-05-14 | The election of four Class III directors to serve until our 2029 annual meeting of stockholders and until their successors are duly elected and qualified. Andreas Wicki, Ph.D. | Withhold | FOR — 21 of 21 Fidelity funds | Against | Elected, 54.0% support |
| Harmony Biosciences Holdings, Inc. | 2026-05-14 | The election of four Class III directors to serve until our 2029 annual meeting of stockholders and until their successors are duly elected and qualified. Troy Ignelzi | Withhold | FOR — 22 of 22 Fidelity funds | Against | Elected, 70.6% support |
| Acadia Pharmaceuticals Inc. | 2026-05-29 | To elect the Board's three nominees for Class I director to hold office until the Company's 2029 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Edmund P. Harrigan, M.D. | Withhold | FOR — 19 of 19 Fidelity funds | Against | Passed (calculated), 85.4% support |
| Sarepta Therapeutics, Inc. | 2026-06-04 | To elect, as Class I directors to hold office until the 2028 Annual Meeting of Stockholders and until their successors are elected and qualified or their earlier death, resignation or removal, the following director nominees: Deirdre Connelly | Against | FOR — 19 of 19 Fidelity funds | Against | Elected, 79.0% support |
| Ocular Therapeutix, Inc. | 2026-06-10 | To approve an advisory vote on named executive officer compensation. | Against | FOR — 28 of 29 Fidelity funds | Against | — |
| Company | Meeting | Item | This fund | Most Fidelity funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| Aveanna Healthcare Holdings Inc. | 2026-05-29 | To approve, on an advisory, non-binding, basis, the compensation paid to the Company's Named Executive Officers identified in the accompanying Proxy Statement. | Against | FOR — 18 of 18 Fidelity funds | Against | Passed (calculated), 89.1% support |
| Aveanna Healthcare Holdings Inc. | 2026-05-29 | To elect the three Class II director nominees identified in the accompanying Proxy Statement to the Board of Directors of the Company, each to serve a three-year term expiring at the 2029 Annual Meeting of the Company's stockholders: Steven E. Rodgers | Withhold | FOR — 17 of 17 Fidelity funds | Against | Passed (calculated), 93.7% support |
| NewAmsterdam Pharma Company N.V. | 2026-06-02 | Extension of authorization for the Board of Directors to issue ordinary shares (or rights to subscribe for ordinary shares) in the Company's capital. | Against | FOR — 26 of 27 Fidelity funds | Against | Approved, 69.0% support |
| NovoCure Limited | 2026-06-03 | The approval of our amended and restated 2024 Omnibus Incentive Plan. | For | AGAINST — 18 of 18 Fidelity funds | For | Approved, 50.3% support |
| STAAR Surgical Company | 2026-01-06 | A proposal to approve, on an advisory (nonbinding) basis, the compensation that may be paid or become payable to STAAR's named executive officers that is based on or otherwise relates to the Merger Agreement and the transactions contemplated by the Merger Agreement. | Against | FOR — 17 of 17 Fidelity funds | Against | Not approved, 33.8% support |
| Alphatec Holdings, Inc. | 2026-06-10 | To elect seven persons to our Board of Directors: Quentin Blackford | Withhold | FOR — 17 of 17 Fidelity funds | Against | Passed (calculated), 71.1% support |
| IRadimed Corporation | 2026-06-23 | Election of Directors: Monty Allen | Withhold | FOR — 18 of 18 Fidelity funds | Against | Elected, 87.3% support |
| Sana Biotechnology, Inc. | 2026-06-04 | To elect three Class II directors to our Board of Directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders or until his or her respective successor is duly elected and qualified. The nominees for election are: Alise S. Reicin, M.D. | Withhold | FOR — 17 of 17 Fidelity funds | Against | — |
| CorVel Corporation | 2025-08-07 | To elect six directors, each to serve until the annual meeting of stockholders to be held in 2026 or until his or her successor has been duly elected and qualified: R. Judd Jessup | Withhold | FOR — 16 of 16 Fidelity funds | Against | Passed (calculated), 87.6% support |
| Celcuity Inc. | 2026-05-14 | To approve, on an advisory basis, named executive officer compensation. | For | AGAINST — 16 of 16 Fidelity funds | For | Passed (calculated), 95.1% support |
| LeMaitre Vascular, Inc. | 2026-06-02 | Election of Directors: John A. Roush | Withhold | FOR — 16 of 16 Fidelity funds | Against | — |
| Bio-Rad Laboratories, Inc. | 2026-04-21 | Nominees: Arnold A. Pinkston | For | AGAINST — 15 of 15 Fidelity funds | For | Passed (calculated), 88.8% support |
| Bio-Rad Laboratories, Inc. | 2026-04-21 | Nominees: Melinda Litherland | For | AGAINST — 15 of 15 Fidelity funds | For | Passed (calculated), 88.3% support |
| CorVel Corporation | 2025-08-07 | To elect six directors, each to serve until the annual meeting of stockholders to be held in 2026 or until his or her successor has been duly elected and qualified: Jeffrey J. Michael | Withhold | FOR — 15 of 15 Fidelity funds | Against | Passed (calculated), 84.4% support |
| Celcuity Inc. | 2026-05-14 | To approve the Celcuity Inc. Amended and Restated Employee Stock Purchase Plan. | Against | FOR — 15 of 15 Fidelity funds | Against | — |
| Agios Pharmaceuticals, Inc. | 2026-06-18 | To elect each of the three Class I director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: Cynthia Smith | Withhold | FOR — 15 of 15 Fidelity funds | Against | Passed (calculated), 68.3% support |
| Wave Life Sciences Ltd. | 2025-08-05 | The election of the nominees for director: Christian Henry | Against | FOR — 15 of 15 Fidelity funds | Against | Passed (calculated), 85.4% support |
| ImmunityBio, Inc. | 2026-06-09 | Election of Directors: Linda Maxwell, M.D. | Withhold | FOR — 14 of 14 Fidelity funds | Against | Elected, 97.9% support |
| Guardian Pharmacy Services, Inc. | 2026-05-05 | To elect Class II directors, to hold office until the annual meeting of stockholders to be held in 2029 and until their successors are duly elected and qualified: John Ackerman | For | WITHHOLD — 14 of 14 Fidelity funds | For | Elected, 82.3% support |
| Guardian Pharmacy Services, Inc. | 2026-05-05 | To elect Class II directors, to hold office until the annual meeting of stockholders to be held in 2029 and until their successors are duly elected and qualified: Randall Lewis | Withhold | FOR — 14 of 14 Fidelity funds | Against | Elected, 82.6% support |
| Perrigo Company plc | 2026-04-30 | To elect, by separate resolutions, nine director nominees to serve until the 2027 Annual General Meeting of Shareholders: Albert A. Manzone | Against | FOR — 14 of 14 Fidelity funds | Against | Passed (calculated), 85.9% support |
| Azenta, Inc. | 2026-01-28 | Election of Directors: Tina S. Nova | Withhold | FOR — 14 of 14 Fidelity funds | Against | Elected, 82.2% support |
| Phibro Animal Health Corporation | 2025-11-04 | Election of Class III Directors: E. Thomas Corcoran | Withhold | FOR — 21 of 22 Fidelity funds | Against | Elected, 96.0% support |
| STAAR Surgical Company | 2026-01-06 | A proposal to adopt the Agreement and Plan of Merger, dated as of August 4, 2025, as may be amended from time to time (the "Merger Agreement"), by and among STAAR Surgical Company ("STAAR"), Alcon Research, LLC, a Delaware limited liability company ("Alcon"), and Rascasse Merger Sub, Inc., a Delawar | Against | FOR — 14 of 14 Fidelity funds | Against | Not approved, 35.3% support |
| Arbutus Biopharma Corporation | 2026-05-26 | To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2027 Annual General and Special Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Matthew Gline | Withhold | FOR — 14 of 14 Fidelity funds | Against | Passed (calculated), 86.5% support |
| ARS Pharmaceuticals, Inc. | 2026-06-24 | To elect our Board of Directors' three nominees for Class III director named in the accompanying proxy statement to serve for three-year terms until the 2029 Annual Meeting of Stockholders: Phillip Schneider | Withhold | FOR — 14 of 14 Fidelity funds | Against | Elected, 58.3% support |
| Palvella Therapeutics, Inc. | 2026-06-10 | Approval of an adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve Proposal 5. | For | AGAINST — 13 of 13 Fidelity funds | For | Passed (calculated), 75.2% support |
| Palvella Therapeutics, Inc. | 2026-06-10 | Approval of an amendment to the 2024 Equity Incentive Plan to increase the authorized shares issuable under the 2024 Plan by 750,000 shares. | For | AGAINST — 13 of 13 Fidelity funds | For | — |
| Avidity Biosciences, Inc. | 2026-02-26 | To approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to our named executive officers in connection with the transactions contemplated by the Merger Agreement and the Separation Agreement. | Against | FOR — 20 of 21 Fidelity funds | Against | Approved, 82.4% support |
| Taysha Gene Therapies, Inc. | 2026-06-01 | To elect the Board's Class III Director nominees, Sean P. Nolan and Laura Sepp-Lorenzino, Ph.D. to the Board of Directors to hold office until the 2029 Annual Meeting of Stockholders: Laura Sepp-Lorenzino, Ph.D. | Withhold | FOR — 19 of 20 Fidelity funds | Against | Elected, 73.3% support |
| OPKO Health, Inc. | 2026-06-18 | To elect as directors the eleven nominees named in the attached proxy statement for a term of office expiring at the 2027 annual meeting of stockholders or until their respective successors are duly elected and qualified: John A. Paganelli | For | AGAINST — 12 of 12 Fidelity funds | For | Elected, 85.8% support |
| OPKO Health, Inc. | 2026-06-18 | To elect as directors the eleven nominees named in the attached proxy statement for a term of office expiring at the 2027 annual meeting of stockholders or until their respective successors are duly elected and qualified: Steven D. Rubin | For | AGAINST — 12 of 12 Fidelity funds | For | Elected, 88.2% support |
| Merus N.V. | 2025-12-09 | Appointment of Anthony Pagano as non-executive director of Merus | For | AGAINST — 12 of 12 Fidelity funds | For | — |
| Merus N.V. | 2025-12-09 | Appointment of Greg Mueller as non-executive director of Merus | For | AGAINST — 12 of 12 Fidelity funds | For | — |
| Merus N.V. | 2025-12-09 | Appointment of Martine van Vugt, Ph.D., as non-executive director of Merus | For | AGAINST — 12 of 12 Fidelity funds | For | — |
| SI-BONE, Inc. | 2026-06-04 | Election of Directors: Jeffrey W. Dunn | Withhold | FOR — 11 of 11 Fidelity funds | Against | Elected, 63.4% support |
| Ginkgo Bioworks Holdings, Inc. | 2026-06-11 | Election of Directors: Christian Henry | Against | FOR — 11 of 11 Fidelity funds | Against | Elected, 87.1% support |
| Ginkgo Bioworks Holdings, Inc. | 2026-06-11 | Election of Directors: Harry E. Sloan | For | AGAINST — 11 of 11 Fidelity funds | For | Elected, 90.0% support |
| Ginkgo Bioworks Holdings, Inc. | 2026-06-11 | Election of Directors: Ross Fubini | For | AGAINST — 11 of 11 Fidelity funds | For | Elected, 92.6% support |
| CorMedix Inc. | 2026-06-23 | Election of Directors: Myron Kaplan | Withhold | FOR — 11 of 11 Fidelity funds | Against | Elected, 87.4% support |
| Tempus AI, Inc. | 2026-05-21 | To elect nine directors to serve until the next annual meeting and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Wayne A.I. Frederick, M.D. | Withhold | FOR — 10 of 10 Fidelity funds | Against | Passed (calculated), 99.3% support |
| NewAmsterdam Pharma Company N.V. | 2026-06-02 | Extension of authorization for the Board of Directors to limit or exclude pre-emption rights. | Against | FOR — 24 of 27 Fidelity funds | Against | Approved, 67.0% support |
| UroGen Pharma Ltd. | 2026-06-22 | To elect to the Board of Directors each of the following seven nominees presented by the Board of Directors to hold office until the Company's next annual meeting of shareholders: Arie Belldegrun, M.D. | Against | FOR — 9 of 9 Fidelity funds | Against | Elected, 82.5% support |
| GoodRx Holdings, Inc. | 2026-06-16 | Election of Directors: Gregory Mondre | Withhold | FOR — 9 of 9 Fidelity funds | Against | Passed (calculated), 99.7% support |
| Ardelyx, Inc. | 2026-06-16 | To approve the amendment to the Amended and Restated 2014 Equity Incentive Award Plan, or the Restated Plan, to increase the maximum number of shares of common stock that may be delivered pursuant to awards granted under the Restated Plan by 9,000,000 shares. | For | AGAINST — 14 of 15 Fidelity funds | For | Approved, 52.6% support |
| Inhibrx Biosciences, Inc. | 2026-06-03 | To elect two Class II directors, nominated by our Board of Directors, to serve until our 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or until their respective earlier death, resignation, or removal: Douglas G. Forsyth | Withhold | FOR — 9 of 9 Fidelity funds | Against | — |
| ARS Pharmaceuticals, Inc. | 2026-06-24 | To elect our Board of Directors' three nominees for Class III director named in the accompanying proxy statement to serve for three-year terms until the 2029 Annual Meeting of Stockholders: Laura Shawver, Ph.D. | Withhold | FOR — 13 of 14 Fidelity funds | Against | Elected, 68.4% support |
| Hims & Hers Health, Inc. | 2026-06-11 | Election of Directors: Andrew Dudum | For | WITHHOLD — 12 of 13 Fidelity funds | For | Passed (calculated), 99.1% support |
| Pulse Biosciences, Inc. | 2026-06-11 | Election of Directors: Manmeet S. Soni | Against | FOR — 12 of 13 Fidelity funds | Against | Elected, 95.8% support |
| Clover Health Investments, Corp. | 2026-06-10 | ELECTION OF DIRECTORS: Thomas L. Tran | For | WITHHOLD — 12 of 13 Fidelity funds | For | Elected, 98.3% support |
| Fulgent Genetics, Inc. | 2026-05-14 | Election of Directors: Linda Dong | Withhold | FOR — 12 of 13 Fidelity funds | Against | Passed (calculated), 75.7% support |
| Fulgent Genetics, Inc. | 2026-05-14 | Election of Directors: Regina Groves | Withhold | FOR — 12 of 13 Fidelity funds | Against | Passed (calculated), 73.0% support |
| Standard BioTools Inc. | 2026-06-17 | To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the proxy statement. | For | AGAINST — 12 of 13 Fidelity funds | For | Approved, 85.2% support |
| ARS Pharmaceuticals, Inc. | 2026-06-24 | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the accompanying proxy statement. | For | AGAINST — 15 of 17 Fidelity funds | For | Approved, 87.6% support |
| CRISPR Therapeutics AG | 2026-06-04 | Non-binding advisory vote on the compensation paid to the Company's named executive officers under U.S. securities law requirements. | For | AGAINST — 7 of 7 Fidelity funds | For | Approved, 69.4% support |
| Universal Health Services, Inc. | 2026-05-20 | Election of Director: Nina Chen-Langenmayr | For | WITHHOLD — 20 of 24 Fidelity funds | For | — |
| Celcuity Inc. | 2026-05-14 | Elect eight directors: Leo T. Furcht | Withhold | FOR — 13 of 15 Fidelity funds | Against | Passed (calculated), 85.0% support |
| Ardent Health, Inc. | 2026-05-20 | Election of Directors: Peter Bynoe | Withhold | FOR — 6 of 6 Fidelity funds | Against | Passed (calculated), 95.2% support |
| IRadimed Corporation | 2026-06-23 | Election of Directors: James Hawkins | For | WITHHOLD — 15 of 18 Fidelity funds | For | Elected, 77.7% support |
| IRadimed Corporation | 2026-06-23 | Election of Directors: Roger Susi | For | WITHHOLD — 15 of 18 Fidelity funds | For | Elected, 81.4% support |
| Tempus AI, Inc. | 2026-05-21 | To elect nine directors to serve until the next annual meeting and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Theodore J. Leonsis | For | WITHHOLD — 9 of 10 Fidelity funds | For | Passed (calculated), 94.4% support |
| Aveanna Healthcare Holdings Inc. | 2026-05-29 | To elect the three Class II director nominees identified in the accompanying Proxy Statement to the Board of Directors of the Company, each to serve a three-year term expiring at the 2029 Annual Meeting of the Company's stockholders: Rodney D. Windley | Withhold | FOR — 14 of 17 Fidelity funds | Against | Passed (calculated), 83.5% support |
| HealthStream, Inc. | 2026-05-28 | To elect three Class II directors (A. Alex Jahangir, Jeffrey L. McLaren, and Linda E. Rebrovick) to hold office for a term of three (3) years and until their successors have been duly elected and qualified: Jeffrey L. McLaren | Withhold | FOR — 14 of 17 Fidelity funds | Against | Elected, 58.2% support |
| CRISPR Therapeutics AG | 2026-06-04 | Binding vote on maximum equity for members of the Executive Committee from the 2026 Annual General Meeting to the 2027 annual general meeting of shareholders. | For | AGAINST — 5 of 5 Fidelity funds | For | — |
| CRISPR Therapeutics AG | 2026-06-04 | Binding vote on maximum non-performance-related compensation for members of the Executive Committee from July 1, 2026 to June 30, 2027. | For | AGAINST — 5 of 5 Fidelity funds | For | — |
| CRISPR Therapeutics AG | 2026-06-04 | Binding vote on maximum variable compensation for members of the Executive Committee for the current year ending December 31, 2026. | For | AGAINST — 5 of 5 Fidelity funds | For | — |
| CRISPR Therapeutics AG | 2026-06-04 | Non-binding advisory vote on the 2025 Compensation Report. | For | AGAINST — 5 of 5 Fidelity funds | For | — |
| CRISPR Therapeutics AG | 2026-06-04 | Re-election of Briggs W. Morrison, M.D. | For | AGAINST — 5 of 5 Fidelity funds | For | — |
| CRISPR Therapeutics AG | 2026-06-04 | Re-election of Douglas A. Treco, Ph.D. | Against | FOR — 5 of 5 Fidelity funds | Against | Elected, 91.1% support |
| CRISPR Therapeutics AG | 2026-06-04 | Re-election of H. Edward Fleming, Jr., M.D. | For | AGAINST — 5 of 5 Fidelity funds | For | — |
| CRISPR Therapeutics AG | 2026-06-04 | Re-election of John T. Greene | For | AGAINST — 5 of 5 Fidelity funds | For | — |
| Merus N.V. | 2025-12-09 | Appointment of Anthony Pagano as non-executive director of Merus Opportunity for Merus Shareholders to make recommendations at the EGM to Merus' non-executive directors in respect of their nomination to appoint a non-executive director | For | AGAINST — 10 of 12 Fidelity funds | — | Passed (calculated), 78.5% support |
| Merus N.V. | 2025-12-09 | Appointment of Greg Mueller as non-executive director of Merus Opportunity for Merus Shareholders to make recommendations at the EGM to Merus' non-executive directors in respect of their nomination to appoint a non-executive director | For | AGAINST — 10 of 12 Fidelity funds | — | Passed (calculated), 78.5% support |
| Merus N.V. | 2025-12-09 | Appointment of Martine van Vugt, Ph.D., as non-executive director of Merus Opportunity for Merus Shareholders to make recommendations at the EGM to Merus' non-executive directors in respect of their nomination to appoint a non-executive director | For | AGAINST — 10 of 12 Fidelity funds | — | Passed (calculated), 78.5% support |
| Natera, Inc. | 2026-06-11 | To approve an amendment to Natera's 2015 Equity Incentive Plan, as amended and restated. | For | AGAINST — 31 of 45 Fidelity funds | For | Passed (calculated), 78.1% support |
| TG Therapeutics, Inc. | 2026-06-11 | Election of Directors: Sagar Lonial, MD | Withhold | FOR — 13 of 17 Fidelity funds | Against | Passed (calculated), 54.9% support |
| Edgewise Therapeutics, Inc. | 2026-06-04 | Elect the directors named in the attached Proxy Statement to serve until the 2029 Annual Meeting of Stockholders: Badreddin Edris, Ph.D. | Withhold | FOR — 13 of 17 Fidelity funds | Against | Elected, 70.3% support |
| Edgewise Therapeutics, Inc. | 2026-06-04 | Elect the directors named in the attached Proxy Statement to serve until the 2029 Annual Meeting of Stockholders: Jonathan Root, M.D. | Withhold | FOR — 13 of 17 Fidelity funds | Against | Elected, 65.0% support |
| Xeris Biopharma Holdings, Inc. | 2026-06-04 | To elect two Class II directors to our board of directors to serve until the 2029 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: John Johnson | Withhold | FOR — 13 of 17 Fidelity funds | Against | Elected, 60.2% support |
| Capricor Therapeutics, Inc. | 2026-06-04 | ELECTION OF DIRECTORS: Frank Litvack | Withhold | FOR — 13 of 17 Fidelity funds | Against | Passed (calculated), 68.6% support |
| Sana Biotechnology, Inc. | 2026-06-04 | To elect three Class II directors to our Board of Directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders or until his or her respective successor is duly elected and qualified. The nominees for election are: Hans E. Bishop | Withhold | FOR — 13 of 17 Fidelity funds | Against | — |
| Doximity, Inc. | 2025-08-28 | To elect two Class I Directors to serve until the annual meeting of stockholders to be held in 2028 or until their successors are duly elected and qualified: Kira Wampler | Withhold | FOR — 33 of 52 Fidelity funds | Against | Elected, 91.7% support |
| Scholar Rock Holding Corporation | 2026-06-04 | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers. | Against | FOR — 26 of 40 Fidelity funds | Against | Approved, 61.7% support |
| Henry Schein, Inc. | 2026-05-21 | Election of Incumbent Directors: Max Lin | Against | FOR — 18 of 27 Fidelity funds | Against | Passed (calculated), 77.3% support |
| LifeStance Health Group, Inc. | 2026-06-02 | Election of two director nominees named in the Proxy Statement to serve until the 2029 Annual Meeting of Stockholders: David Bourdon | For | WITHHOLD — 25 of 39 Fidelity funds | For | Elected, 74.5% support |
| Nuvation Bio Inc. | 2026-05-21 | Election of Directors: Robert Bazemore | For | WITHHOLD — 12 of 17 Fidelity funds | For | Elected, 84.0% support |
| Stryker Corporation | 2026-05-06 | Election Directors: Emmanuel P. Maceda | For | AGAINST — 22 of 36 Fidelity funds | For | Elected, 81.9% support |
| Stryker Corporation | 2026-05-06 | Election Directors: Ronda E. Stryker | For | AGAINST — 22 of 37 Fidelity funds | For | Elected, 96.6% support |
| Progyny, Inc. | 2026-05-21 | Election of Directors: Cheryl Scott | For | WITHHOLD — 14 of 23 Fidelity funds | For | Elected, 76.2% support |
| Arrowhead Pharmaceuticals, Inc. | 2026-03-19 | Election of Directors: Michael S. Perry | Against | FOR — 13 of 22 Fidelity funds | Against | — |
| Immunovant, Inc. | 2025-08-27 | To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2026 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Douglas Hughes | Withhold | FOR — 16 of 28 Fidelity funds | Against | Elected, 89.5% support |
| Stoke Therapeutics, Inc. | 2026-06-03 | To approve, on an advisory basis, the compensation of the Company's named executive officers. | For | AGAINST — 17 of 30 Fidelity funds | For | Passed (calculated), 72.9% support |
| Nurix Therapeutics, Inc. | 2026-05-15 | To approve, a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement. | For | AGAINST — 16 of 28 Fidelity funds | For | — |
| uniQure N.V. | 2026-06-10 | Resolution to adopt the amendment to the Articles of Association to reflect Dutch large company regime. | For | AGAINST — 10 of 16 Fidelity funds | For | Approved, 74.5% support |
| Phibro Animal Health Corporation | 2025-11-04 | Election of Class III Directors: Jack C. Bendheim | For | WITHHOLD — 13 of 22 Fidelity funds | For | Elected, 96.8% support |
| Stoke Therapeutics, Inc. | 2026-06-03 | Election of Class I Directors to serve until the 2029 annual meeting of stockholders or until their successor has been duly elected and qualified or until their earlier resignation or removal: Julie Anne Smith | For | WITHHOLD — 14 of 27 Fidelity funds | For | Passed (calculated), 86.9% support |
| UroGen Pharma Ltd. | 2026-06-22 | To approve the amendment and restatement of the Articles of Association of the Company to, among other things, tie eligibility for shareholder proposals to the requirements under the Israeli Companies Law. | For | AGAINST — 5 of 9 Fidelity funds | For | Approved, 68.2% support |
Download all 122 differences (CSV)
The same votes as “with management” above, by the sector of the company voted on. 98.7% of this fund’s 2,820 such votes could be given a sector; the other 38 (1.3%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 2,502 | 43 | 1.7% |
| Industrials | 129 | 2 | 1.6% |
| Technology | 67 | 0 | 0.0% |
| Consumer Discretionary | 55 | 1 | 1.8% |
| Consumer Staples | 21 | 1 | 4.8% |
| Finance | 8 | 0 | 0.0% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 1,856 | 9 |
| Say-on-Pay | 352 | 0 |
| Audit-related | 337 | 0 |
| Compensation | 145 | 2 |
| Corporate Governance | 95 | 26 |
| Capital Structure | 41 | 0 |
| Extraordinary Transactions | 18 | 0 |
| Shareholder Rights and Defenses | 10 | 1 |
| Other Social Issues | 5 | 5 |
| Environment or Climate | 3 | 3 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Eli Lilly and Company | May 4, 2026 | $513M | 10 | 2 |
| Johnson & Johnson | April 23, 2026 | $303M | 15 | 1 |
| AbbVie Inc. | May 8, 2026 | $234M | 8 | 1 |
| UnitedHealth Group Incorporated | June 1, 2026 | $168M | 12 | 1 |
| Merck & Co., Inc. | May 26, 2026 | $162M | 18 | 3 |
| Thermo Fisher Scientific Inc. | May 20, 2026 | $117M | 13 | 0 |
| Amgen Inc. | May 19, 2026 | $112M | 15 | 1 |
| Gilead Sciences, Inc. | April 30, 2026 | $93M | 15 | 3 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposal | Against | For |
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to prepare an annual lobbying report. Shareholder proposal | Against | For |
| April 23, 2026 | Johnson & Johnson | Independent Board Chair Shareholder proposal | Against | For |
| May 8, 2026 | AbbVie Inc. | Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposal | Against | For |
| June 1, 2026 | UnitedHealth Group Incorporated | If properly presented at the 2026 Annual Meeting of Shareholders, the shareholder proposal requesting the adoption of a policy to require any Board Chair to be independent. Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposal | Against | For |
| May 19, 2026 | Amgen Inc. | Stockholder proposal to require an independent board chairman. Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| April 23, 2026 | Pfizer Inc. | Adopt an Independent Chair Policy Shareholder proposal | Against | For |
| May 13, 2026 | Vertex Pharmaceuticals Incorporated | Shareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposal | Against | For |
Meetings with a proxy contest or competing nominees (3 in 2025-2026), and how the fund voted the items on its ballot.
2,863 ballot items at 347 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, Fidelity MSCI Health Care Index ETF (FHLC) voted at 347 shareholder meetings of 333 companies, on 2,863 ballot items in all. Where management made a recommendation, the fund followed it on 98.3% of the items and voted against it 47 times. Its most frequent area of disagreement was corporate governance (26 of its votes against management). It voted on 47 shareholder proposals. It voted FOR the board's own proposals more often than Fidelity's funds as a whole (95.8% against 94.1%). It voted differently from most Fidelity funds on 122 items. 3 of its meetings were contested.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Fidelity’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.